These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1384134)

  • 21. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
    Rodriguez-Monge EJ; Cabanillas F
    Hematol Oncol Clin North Am; 1997 Oct; 11(5):937-47. PubMed ID: 9336723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
    Wilder RB; Rodriguez MA; Tucker SL; Ha CS; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):743-9. PubMed ID: 11395243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
    Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
    Cabanillas F; Rodriguez-Diaz Pavón J; Hagemeister FB; McLaughlin P; Rodriguez MA; Romaguera JE; Dong K; Moon T
    Ann Oncol; 1998 May; 9(5):511-8. PubMed ID: 9653492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-hodgkins lymphoma.
    Mead G; Woodcock J; Young C
    Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of mitoxantrone in non-Hodgkin's lymphoma.
    Armitage JO
    Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
    Dincol D; Buyukcelik A; Dogan M; Akbulut H; Samur M; Demirkazik A; Senler FC; Onur H; Icli F
    Med Oncol; 2010 Sep; 27(3):942-5. PubMed ID: 19787462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
    Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
    Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
    Gerhartz HH; Wilmanns W; Brittinger G; Engelhard M; Heinz R; Huhn D; Meusers P; Siegert W; Stacher A; Thiel E
    Onkologie; 1989 Feb; 12(1):22-6. PubMed ID: 2470000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
    Rodriguez MA; Cabanillas FC; Hagemeister FB; McLaughlin P; Romaguera JE; Swan F; Velasquez W
    Ann Oncol; 1995 Jul; 6(6):609-11. PubMed ID: 8573542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
    McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Romaguera J; Rodriguez MA; Lee MS; Pate O; Sarris A; Younes A
    Ann Oncol; 1994; 5 Suppl 2():73-7. PubMed ID: 7515650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
    Fernández de Larrea C; Martínez C; Gaya A; López-Guillermo A; Rovira M; Fernández-Avilés F; Lozano M; Bosch F; Esteve J; Nomdedeu B; Montserrat E; Carreras E
    Ann Oncol; 2010 Jun; 21(6):1211-1216. PubMed ID: 19889622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
    Oztürk MA; Barişta I; Altundağ MK; Türker A; Yalçin S; Celik I; Güllü I; Güler N; Ozişik Y; Kars A; Kansu E; Baltali E; Tekuzman G
    Chemotherapy; 2002 Dec; 48(5):252-8. PubMed ID: 12476042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
    Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Rodriguez J; Preti A; Younes A; Sarris AH; Cabanillas F
    Invest New Drugs; 1999; 17(2):187-92. PubMed ID: 10638491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.